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The numerous descriptions of regulatory T 
(T reg) cells in both animal models and, more 
recently, in humans have revealed a wide diver-
sity of populations and mechanisms of action. 
Thymically derived CD4+CD25+ T reg cells 
play a crucial role in the maintenance of self-
tolerance and the prevention of autoimmune 
disease. This “natural” subset expresses the tran-
scription factor Foxp3, which has emerged as 
an important functional marker of T reg cell 
  activity, supported by the fact that ectopic 
Foxp3 expression is suffi   cient to empower naive 
T cells with a regulatory function (1). CD4+ T 
reg cells can also be generated in the periphery 
(adaptive), and many studies have identifi  ed 
diff  erent subpopulations of CD4+ T cells based 
on phenotypic and functional properties (2, 3). 
Examples include IL-10–secreting Tr1 cells, 
which can inhibit colitis in mice (4, 5), and 
Th3 cells, which play a role in mediating toler-
ance via the production of TGF-β (6). TGF-β 
has also been shown to mediate suppression by 
CD4+CD25+ T reg cells in murine models of 
autoimmunity (7). In addition, TGF-β can also 
confer a suppressive phenotype on polyclonally 
activated naive T cells in vitro, leading to an 
expansion of FoxP3+ T reg cells (8–10).
The manipulation of the peripheral pool of 
T reg cells has been a particular focus for the 
treatment of autoimmune diseases and trans-
plantation. Our previous data showing that T 
reg cells from patients with rheumatoid arthri-
tis (RA) are functionally defective, and that 
  after infl  iximab therapy this defect is reversed, 
have emphasized the potential of biological 
therapy (11). An intriguing observation was 
the increased number of peripheral blood 
CD4+CD25hi T reg cells seen only in RA pa-
tients responding to infl  iximab. Thus, TNF-α 
blockade might, as a consequence of the re-
duced infl  ammation, either “recall” T reg cells 
from previously infl  amed joints or lead to the 
diff  erentiation of “new” T reg cells. Here, we 
demonstrate that infl  iximab treatment induced 
the diff  erentiation of a population of T reg cells 
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expressing Foxp3 and low levels of CD62L through conver-
sion of CD4+CD25− T cells.
RESULTS AND DISCUSSION
The expanded population of T reg cells from infl  iximab-
treated patients is Foxp3+ and CD62L−
First, we addressed whether the increased number of 
CD4+CD25hi T cells observed in RA patients responding to 
infl  iximab therapy corresponded to an increase of T reg cells 
or simply refl  ected an increase in the percentage of activated 
T cells. Peripheral CD4+ T cells isolated from healthy, active 
RA patients and those treated with infl  iximab were analyzed 
for the expression of the transcription factor Foxp3 by intra-
cellular staining. A two- to threefold increase in the percentage 
of CD4+Foxp3+ cells was observed in the PBMCs of post-
infl  iximab patients compared with active RA patients or 
healthy individuals, suggesting that the increase in CD25 ex-
pression in post-anti–TNF-α–treated patients refl  ects in-
creased numbers of T reg cells (Fig. 1 A). There was no 
signifi  cant diff  erence in FoxP3 expression in CD4+ T cells 
from active RA patients compared with healthy controls. To 
better characterize the phenotype of the T reg cells after 
  infl  iximab, we measured surface markers representative of 
  activation, memory, and regulation. A signifi  cant increase in 
the percentage of CD4+CD25hiCD62L− was observed in 
PMBCs from infl  iximab-treated patients compared with RA 
patients with active disease before infl  iximab and healthy 
individuals (Fig. 1 B). As previous data has indicated that the 
Figure 1.  Increased numbers of Foxp3+CD62L−CD4+ T cells found 
in infl  iximab-treated RA patients compared with patients with 
  active disease and healthy controls. (A) Representative FACS plots gated 
on the CD4+ population depicting PBMCs from healthy controls, active 
RA patients, and infl  iximab-treated RA patients stained with anti-CD4 and 
anti-Foxp3. The percentages of Foxp3+ cells in the CD4+ gate for individual 
RA patients, before and after infl  iximab, and healthy controls are shown 
in the chart. (B) Histograms were gated on CD4+CD25high cells (as indicated), 
and the expression of CD62L is shown. (C) PBMCs from the same 
groups as in A were stained with anti-CD4, anti-Foxp3, and anti-CD62L. 
The histograms indicate the expression of CD62L in the CD4+Foxp3+ 
  population. Data from individual patients are shown in the chart. 
(D) CCR7 and CD45RO expression on the CD4+Foxp3+ T cell population 
in the different patient groups. (E) CCR7 and CD45RO expression on 
the CD4+FoxP3+CD62L− population from an RA patient treated with 
infl  iximab. Results are representative of six patients or healthy individuals 
for each group. The dashed line in the FACS plots represents the isotype 
control for the specifi  c marker examined.JEM VOL. 204, January 22, 2007  35
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most potent CD4+CD25hi T reg cell subset expressed CD62L 
(12), we next assayed the expression of CD62L in the 
CD4+Foxp3+ population. Although most CD4+Foxp3+ 
cells from healthy individuals and patients with active RA 
expressed CD62L, the profi  le of expression was remarkably 
diff  erent after infl  iximab treatment, where the majority of 
CD4+Foxp3+ cells expressed low levels of CD62L (Fig. 
1 C). There was no change in the percentage of Foxp3+ cells 
or shift in CD62L expression in patients responding to metho-
trexate (not depicted). Compared with the T reg cells found 
in healthy individuals and patients with active disease, RA T 
reg cells post-infl  iximab expressed CD45RO but had a re-
duced expression of CCR7 (Fig. 1 D). Further examination 
of the CD4+Foxp3+CD62L− RA T reg cells post-infl  iximab 
revealed that these cells lacked CCR7 expression and remained 
CD45RO+ (Fig. 1 E).
CD62L− T reg cells from infl  iximab-treated RA patients 
mediate their suppressive action through TGF-𝗃 and IL-10
We next tested whether the CD4+CD25hiCD62L− T reg 
cells isolated from infl  iximab-treated patients were function-
ally suppressive. CD4+CD25hi were FACS sorted according 
to their expression of CD62L (identifi  ed as CD62L+ and 
CD62L− T reg cells; Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20061531/DC1), and their regula-
tory capacity was assessed with respect to inhibition of pro-
liferation and TNF-α and IFN-γ production by autologous 
CD4+CD25− T cells. In agreement with previous studies 
(12), CD62L+ T reg cells isolated from healthy individuals 
were more potent at suppressing CD4+CD25− T cell pro-
liferation than CD62L− T reg cells (Fig. 2 A). Conversely, 
CD62L− T reg cells isolated from RA patients after infl  ix-
imab exhibited a more potent suppression of T cell prolifera-
tion than their CD62L+ T reg cell counterparts. Similarly, 
we observed a “switch” in the suppressor population from 
CD62L+ T reg cells in healthy individuals to CD62L− T reg 
cells in patients after infl  iximab, with respect to inhibition of 
IFN-γ and TNF-α production (Fig. 2 B). There was a sub-
stantial reduction in the suppressor potency of CD62L+ T 
reg cells isolated from patients with active RA compared 
with healthy individuals, confi  rming that CD4+CD25hi T 
reg cells are defective in RA patients (11). Of importance, 
the potency of the CD62L+ T reg cells after anti–TNF-α 
therapy was not restored to levels found in healthy controls 
(Fig. 2 B). Collectively, these results raise the intriguing 
  possibility that the natural T reg cells (CD62L+ T reg cells) 
remain defective in patients even after infl  iximab therapy, 
and that the previously reported restoration of function of 
CD4+CD25hi T reg cells after infl  iximab therapy could be 
due to the diff  erentiation of a new population of CD62L− 
T reg cells.
To explore the eff  ector mechanisms of the CD62L− T 
reg cells derived from post-infl  iximab RA patients, we exam-
ined the cytokine dependency of their suppressive eff  ect. 
T reg cells were cocultured with autologous CD4+CD25− T 
cells in the presence of neutralizing mAbs to TGF-β and 
IL-10, previously recognized as regulatory cytokines involved 
in the suppressive mechanism of adaptive T reg cells (2). The 
data shown in Fig. 2 C demonstrate that in healthy individu-
als, the suppressive eff  ect of CD62L− T reg cells was unal-
tered by the neutralization of TGF-β or IL-10. In contrast, 
Figure 2.  CD62L− T reg cells from infl  iximab-treated RA patients 
are more potent suppressors than their CD62L+ counterparts and 
mediate their suppressive effects through IL-10 and TGF-𝗃. 
CD4+CD25−, CD4+CD25hiCD62L+, and CD4+CD25hiCD62L− were FACS 
(MoFlo) sorted from the PBMCs of healthy controls, active RA patients, and 
infl  iximab-treated RA patients. In all experiments, cells were stimulated 
with 2 μg/ml of soluble anti-CD3/CD28. (A) CD4+CD25− T cells were 
  cocultured with either CD62L+ or CD62L− T reg cells (2:1 ratio shown) for 
5 d, with [3H]thymidine added in the last 18 h of culture. Mean triplicate 
values shown from six patients. (B) CD4+CD25− T cells were cultured 
alone or cocultured at a 2:1 ratio with either CD62L+ or CD62L− T reg 
cells for 48 h. Cells were intracellularly stained for TNF-α and IFN-γ. Data 
shown expressed as mean ± SE of six patients and six healthy controls, 
and are represented as the percentage inhibition of cytokine production 
compared with CD4+CD25− T cells alone. The means for percent IFN-γ+/
TNF-α+ cells are as follows: healthy CD4+CD25− 3.2/3.4, CD4+CD25−/
CD62L+ T reg cells 0.7/0.9, CD4+CD25−/CD62L− T reg cells 1.9/2.1; active 
RA CD4+CD25− 5.2/13.2, CD4+CD25−/CD62L+ T reg cells 3.6/9.0, 
CD4+CD25−/CD62L− T reg cells 3.1/7.8; post-infl  iximab CD4+CD25− 
4.2/8.6, CD4+CD25−/CD62L+ T reg cells 3.8/6.3; and CD4+CD25−/CD62L− 
T reg cells 1.1/2.2. (C) CD4+CD25− T cells from healthy and infl  iximab-
treated RA patients were cultured alone or with CD62L− T reg cells 
(2:1 ratio) for 48 h with anti-CD3/CD28 alone or in the presence of 2 μg/ml 
anti–TGF-β1, 0.5 μg/ml anti–IL-10, or anti–TGF-β1 and anti–IL-10   together, 
and stained for TNF-α and IFN-γ. Data depicted represent mean ± SE 
of six patients and healthy controls. (D) CD4+CD25– T cells were 
  cocultured, either directly or separated by a transwell membrane, with 
CD62L− T reg cells from RA patients after infl  iximab, and stimulated with 
2 μg/ml anti-CD3/CD28 for 48 h. Cells were intracellularly stained for 
TNF-α and IFN-γ, and the results are depicted as the percentage inhibition 
of cytokine production compared with CD4+CD25– T cells alone. 
Data represent mean ± SE of four patients.36  DIFFERENTIATION OF REGULATORY T CELLS BY ANTI–TNF-α THERAPY | Nadkarni et al. 
the neutralization of TGF-β, and to a lesser extent IL-10, 
signifi  cantly impaired the suppressive capacity of the CD62L− 
T reg cells from infl  iximab-treated patients. When the action 
of both TGF-β and IL-10 was blocked, the suppressive activ-
ity of these CD62L− T reg cells was almost abolished. The 
potency of CD62L+ T reg cells from healthy individuals was 
unaltered by blockade of IL-10 or TGF-β (not depicted). 
The results reported here appear at odds with our previous 
fi  ndings showing that suppression required contact between 
T reg cells isolated from infl  iximab patients and their auto-
logous CD4+CD25− T cells (11). However, the two results 
may not be directly comparable because in the previous 
work, suppression was assayed without separating the 
CD62L+ and CD62L− T reg cell subsets. Therefore, we as-
sayed the functional properties of purifi  ed CD62L− T reg 
cells isolated from RA patients after infl  iximab therapy to 
  dissect out their mode of action. The data shown in Fig. 
2 D demonstrate that cell contact is required to eff  ect 
  maximal suppression of TNF-α and IFN-γ production by 
CD4+CD25− T cells, although some cytokine suppression is 
still observed when cell contact is prevented. The fact that 
the T reg cells isolated from patients after infl  iximab required 
both cell contact and cytokines for their suppressive eff  ect 
could be explained by data indicating that TGF-β can medi-
ate suppression through cell contact, when the predominant 
form of TGF-β is membrane bound (13). In addition, in 
some experimental systems, IL-10 production also depends on 
cell contact between T reg cells and CD4+CD25− T cells (14). 
Collectively, these results suggest that infl  iximab  therapy 
gives rise to, or recruits from the periphery, a population of 
T reg cells that phenotypically and functionally diff  ers from 
natural T reg cells present in healthy individuals or in patients 
with active RA.
In vitro infl  iximab stimulation of CD4+CD25− T cells 
from RA patients induced a CD62L− T reg cell population
To investigate the possible provenance of CD62L− T reg 
cells, infl  iximab was added in vitro to CD4+CD25− T cells 
isolated from active RA or healthy individuals, and the ex-
pression of Foxp3 was measured by intracellular staining. The 
addition of infl  iximab to purifi  ed active RA CD4+CD25− 
T cells resulted in a substantial increase in the percentage of 
CD4+Foxp3+ cells (Fig. 3 A), whereas no such eff  ect was 
seen when CD4+CD25− T cells were isolated from healthy 
individuals. Neutralization of TGF-β in this culture system 
completely prevented the diff  erentiation of the CD4+Foxp3+ 
T cell population from the CD4+CD25− T cells (Fig. 3 A). 
Moreover, infl  iximab induced a signifi  cant increase in TGF-β 
production from CD4+CD25− T cells from patients with 
active RA, but not healthy individuals (Fig. 3 B). To de-
termine whether infl  iximab modulates natural T reg cell 
Foxp3 expression, CD4+CD25hi T cells were isolated from 
healthy individuals or patients with active RA and cultured 
with infl  iximab. The results in Fig. 3 C show that infl  iximab 
Figure 3.  The addition of infl  iximab in vitro to activated RA 
CD4+CD25− T cells induced a population of FoxP3+ T cells that 
were functionally suppressive. (A) Purifi  ed CD4+CD25− T cells from 
both healthy controls and active RA patients were stimulated with 2 μg/ml 
anti-CD3/CD28, ±10 μg/ml infl  iximab. In some wells, 2 μg/ml anti–
 TGF-β was added. Cells were cultured for 24 h and then intracellularly 
stained for FoxP3. Representative FACS plots are shown as well as the 
pooled data (n = 8 patients and 8 healthy individuals). Percentages shown 
are of the purifi  ed CD4+CD25− fraction. (B) Supernatants were collected 
from cells cultured in A before staining and were tested for TGF-β 
  production by ELISA. (C) Purifi  ed CD4+CD25high T cells from healthy 
  individuals and patients with active RA were incubated with 2 μg/ml 
anti-CD3/CD28, ±10 μg/ml infl  iximab, and the percentages of Foxp3+ 
cells are shown. (D) Histograms depicting CD62L expression in the T cells 
after culture as in A. Black line, isotype control; shaded area, CD62L. 
(E) CD4+CD25+ from the cultures in A were isolated, recultured at a 1:2 ratio 
with freshly isolated autologous CD4+CD25− T cells for an additional 2 d, 
and stained for TNF-α and IFN-γ. Data are depicted as the percentage 
of cytokine inhibition (n = 8).JEM VOL. 204, January 22, 2007  37
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did not aff   ect the expression of FoxP3 on CD4+CD25hi 
T reg cells, supporting the evidence that this agent targets 
CD4+CD25− T cells rather than modulating preexisting 
T reg cells. We next measured CD62L expression after culture 
of CD4+CD25− T cells with infl  iximab. The addition of in-
fl  iximab to CD4+CD25− T cells from active RA patients, but 
not from healthy individuals, led to a reduction in CD62L 
expression (Fig. 3 D). Thus, these in vitro infl  iximab-generated 
T cells share reduced CD62L expression as a common feature 
with the T reg cells present in the PBMCs of RA patients 
that had received infl  iximab therapy.
We sought to confi  rm that the Foxp3+ T cells diff  eren-
tiated upon infl  iximab stimulation possess suppressor activity. 
Because the majority of purifi  ed CD4+CD25− T cells had 
acquired CD25 expression when stimulated with anti-CD3/
CD28, with or without infl  iximab, the CD4+CD25+ T cells 
were purifi  ed and cultured with freshly isolated autolo  gous 
CD4+CD25− T cells. Only the CD4+CD25+ T cells de  rived 
from active RA patients, but not healthy individuals, which 
had been cocultured with infl  iximab, were able to suppress 
production of IFN-γ and TNF-α from freshly isolated 
CD4+CD25− T cells (Fig. 3 E).
The potential of T reg cells to modulate immune re-
sponses has led to considerable interest in their use for the 
treatment of autoimmune disease. Two broad therapeutic ap-
proaches have been considered; fi  rst, to expand T reg cells in 
vitro with the intention of infusing these cells into patients, 
and second, to manipulate the immune system in vivo result-
ing in an increase in T reg cells. Infl  iximab, a monoclonal 
anti–TNF-α antibody, appears to be an example of the latter 
and demonstrates that inhibition of a proinfl  ammatory cyto-
kine can result in an expanded T reg cell population. Infl  ix-
imab led to the diff  erentiation of a population of T reg cells 
identifi   ed as FoxP3+CD25hiCD62L−CCR7− in patients 
with RA. These T reg cells are phenotypically distinct from 
natural T reg cells, which express CD62L and CCR7, but 
also diff  er functionally as their suppressor capacity depends 
on the production of TGF-β and IL-10. Murine studies have 
demonstrated the importance of IL-10 and/or TGF-β 
in providing increased regulatory potency to CD4+CD25+ 
T reg cells in the face of an infl  ammatory response (7, 15, 16) 
or in the prevention of graft rejection (17). In addition, IL-
10–mediated suppression is used by CD4+CD25hiHLA-DR− 
T reg cells found in healthy individuals (18). Of relevance to 
this work, CD4+CD25+CD62L− T reg cells, producing 
both IL-10 and TGF-β, have been identifi  ed in diabetic mice 
treated with a combination of anti-CD3 and insulin (19). In 
patients with diabetes, anti-CD3 therapy expanded a popula-
tion of CD4+CD25+CD62L− T cells (20). Thus, anti-CD3 
treatment in the context of diabetes and anti–TNF-α therapy 
for RA both induce a population of T reg cells with a mem-
ory phenotype (CCR7−CD62L−) (21), perhaps suggesting 
a similar provenance.
The T reg cells found in post-infl   iximab RA patients 
may have arisen either from CD4+CD25− T cells that had 
already begun to diff  erentiate along a Foxp3+ pathway in 
vivo, or from CD4+CD25− responder T cells. The purifi  ed 
CD4+CD25− T cells still contain a small fraction of Foxp3+ 
cells, which could be targeted by infl  iximab. CD127, which 
negatively correlates with Foxp3 expression, could be used 
to further exclude Foxp3+ cells in the CD4+CD25− T cells 
(22). However, TGF-β appeared to mediate the infl  iximab-
driven increase in Foxp3+ T reg cells, which is known to 
target CD4+CD25− T cells rather than natural T reg cells 
(8–10). Moreover, the data shown in Fig. 3 C demonstrate 
that infl  iximab has no eff  ect on CD4+CD25hiFoxp3+ T cells. 
Recent fi  ndings have revealed that TGF-β can also have a 
proinfl  ammatory role dependent on the immunological en-
vironment (23). Thus, in the presence of proinfl  ammatory 
cytokines, TGF-β contributes to the generation of immuno-
pathogenic IL-17–secreting T cells (24–26). Consequently, 
the prerequisite for the generation of T reg cells, rather than 
IL-17–secreting T cells, by TGF-β is the removal of proin-
fl  ammatory cytokines, specifi  cally IL-6, but also TNF-α and 
IL-1. Infl  iximab can serve this function well as it is known 
to rapidly reduce levels of IL-6 (27), the critical partner for 
TGF-β in the production IL-17–producing T cells.
Although Foxp3 expression has been clearly linked to 
T reg cell activity in murine studies, this association has been 
less well established in humans. This is particularly true in the 
context of in vitro activation studies where transient expres-
sion of Foxp3 can occur (28). The ability of infl  iximab to 
confer a suppressive capacity on CD4+CD25− T cells could 
be explained by the presence of activated T cells producing 
the immunoregulatory cytokines IL-10 and TGF-β. These 
T reg cells could be similar to activated Tr1 or Th3 cells identi-
fi  ed by others (4–6).
We have previously shown that CD4+CD25hi T reg cell 
function in RA patients was defective and that this defect 
was reversed after infl  iximab treatment (11). However, the 
data presented here lead to an important reinterpretation of 
our previous fi  nding, specifi  cally that the naturally derived 
T reg cells, defi  ned as CD4+CD25hiCD62L+, appear to remain 
defective after treatment with anti–TNF-α therapy. The res-
toration of function of the CD4+CD25hi population after in-
fl  iximab therapy is most likely to be due to the suppressive 
eff  ects of the newly diff  erentiated CD62L− T reg cells. In 
patients with RA receiving infl  iximab, the diff  erentiation of 
adaptive T reg cells could be further amplifi  ed by their abil-
ity to confer a further suppressive activity on CD4+CD25− 
T cells (29). One could envisage a feedback mechanism 
in which infl   iximab drives the production of TGF-β by 
T cells, which would then induce their diff  erentiation into 
FoxP3+CD62L− T reg cells. Why natural T reg cells remain 
defective after the neutralization of the proinfl  ammatory en-
vironment by infl  iximab is unclear. It is possible that the re-
versal of the proinfl  ammatory milieu by TNF-α blockade 
may only be partial, suffi     cient to allow the generation of 
T reg cells from CD4+CD25− T cells but insuffi   cient to restore 
function to the natural CD62L+ T reg cells. It is tempting to 
speculate that the induction of T reg cells after infl  iximab 
therapy could lead to restoration of tolerance and might partly 38  DIFFERENTIATION OF REGULATORY T CELLS BY ANTI–TNF-α THERAPY | Nadkarni et al. 
explain the exciting observation that infl  iximab can induce 
remission in some patients with early RA after cessation of 
therapy (30). In conclusion, our results indicate that T reg 
cells can be induced, and tolerance restored, by targeting specifi  c 
proinfl  ammatory cytokines such as TNF-α.
MATERIALS AND METHODS
Patient population. 31 patients with active RA, fulfi  lling the revised clas-
sifi  cation criteria of the American College of Rheumatology for RA, were 
evaluated before and 4–6 mo after anti–TNF-α therapy (see reference 11 for 
infl  iximab regime and further details for patient selection and assessment of 
disease activity, all of which remained the same for this study). 20 healthy 
individuals were used as controls. This study was approved by the University 
College London Hospital (UCLH) Ethics Committee.
Antibodies. The following antibodies were used: FITC–anti-CD4 (RPA-
T4), PE-Cy5–anti-CD25 (M-A251), PE–anti-CD62L (Dreg-56), PE–CY7-
anti–TNF-α (Mab11), PE–Cy7-anti–IFN-γ (45.B3), PE-FoxP3 (PCH-101), 
APC–anti-CCR7 (3D12), and PE–anti-CD45RO (UCLH1). T cells were 
activated with soluble anti-CD3 (HIT-3a) and anti-CD28 (CD28.2) as indi-
cated. All antibodies were from BD Biosciences, except FoxP3, which was 
from eBioscience. For neutralization experiments, anti–TGF-β1 (9016.2) and 
anti–human IL-10 (25209) were used (R&D Systems). Infl  iximab, a chimeric 
IgG1 anti–TNF-α mAb, was donated by Schering-Plough.
Cell isolation. Human blood mononuclear cells (PBMCs) were isolated by 
Ficoll-Paque (GE Healthcare) and cultured in RPMI 1640 with 100 
U/μg/ml penicillin/streptomycin (Life Technologies) and 10% FCS (Sera 
Laboratories International, Ltd.). Magnetic bead separation was performed 
as described previously (11), with all magnetic columns and magnetically la-
beled beads purchased from Miltenyi Biotec. To purify cells using FACS 
sorting (MoFlo), cells were stained with the above conjugated antibodies 
(CD4, CD25, and CD62L). Cells were sorted according to gates as indi-
cated in Fig. S1.
Flow cytometric analysis and cytokine detection. Cells were surface 
stained as described previously (11) using the above mentioned conjugated 
antibodies (CD4, CD25, and CD62L). For intracellular analysis of TNF-α 
and IFN-γ production, cells were cultured at 2 × 105 for 48 h with PMA, 
ionomycin, and Golgi Plug added in the fi  nal 5 h of culture. TGF-β1 was 
quantifi  ed using an ELISA kit (R&D Systems). In some experiments, 24-
well transwell plates (Costar) with 0.4-μm membrane supports were used.
Proliferation assays. In all experiments, T reg cells were cultured at 2 × 
105 cells/ml, with CD4+CD25− T cell numbers adjusted accordingly for 
  ratio experiments. Cells were cultured in 96-well U-bottomed plates (Nunc) 
for 5 d with [3H]thymidine added in last 18 h of culture. Proliferation was 
measured using a liquid scintillation counter.
Statistical analysis. Statistical signifi  cance was determined using Student’s 
t test, with p-values <0.05 regarded as statistically signifi  cant.
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